hemorrhag
syndrom
human
anim
host
viru
wide
distribut
throughout
southeastern
europ
middl
east
africa
asia
diseas
manag
proven
difficult
broadli
licens
vaccin
therapeut
recombin
vesicular
stomat
virus
rvsv
express
foreign
glycoprotein
gp
shown
promis
experiment
vaccin
sever
viral
hemorrhag
fever
develop
assess
replic
compet
rvsv
vector
express
cchfv
glycoprotein
precursor
gpc
encod
cchfv
structur
glycoprotein
construct
drive
strong
express
cchfvgp
vitro
use
vector
vaccin
knockout
mice
anim
model
cchfv
vector
toler
efficaci
challeng
clinic
strain
cchfv
anticchfvgp
igg
neutral
antibodi
titer
observ
surviv
anim
studi
demonstr
rvsv
express
cchfvgp
potenti
serv
replic
compet
vaccin
platform
cchf
infect
current
sever
experiment
vaccin
candid
reli
gpc
antigen
compon
evalu
immunocompromis
signal
transduc
activ
transcript
knockout
interferon
receptor
knockout
ifnar
interferon
receptor
antibodi
transient
suppress
mous
model
cchfv
recapitul
clinic
ill
uniformli
lethal
model
cchf
vaccin
candid
approach
focus
either
dna
express
cchfv
antigen
host
tissu
replic
defici
virallik
particl
inactiv
whole
viru
prepar
subunit
antigen
prepar
vector
vaccinia
viru
vaccin
two
prepar
prime
boost
strategi
use
modifi
recombin
vaccinia
viru
strain
ankara
mva
encod
gpc
prime
boost
boost
strategi
dna
base
vaccin
encod
separ
np
g
n
g
c
antigen
provid
promis
result
protect
ifnar
mous
model
cchfv
although
cchfvnp
antigen
mva
vaccin
platform
fail
provid
protect
recombin
vesicular
stomat
virus
rvsv
develop
evalu
promis
experiment
vaccin
sever
pathogen
often
requir
singledos
induc
protect
rvsv
platform
experiment
evalu
durabl
safeti
two
rvsv
vaccin
one
human
immunodefici
viru
hiv
second
zair
ebolaviru
ebov
test
human
clinic
trial
reason
hypothes
rvsv
vector
express
cchfvgpc
could
elicit
protect
respons
lethal
anim
model
cchf
aim
studi
design
gener
character
evalu
rvsv
vector
encod
cchfvgpc
experiment
vaccin
cchfv
crimeancongo
hemorrhag
fever
viru
cchfv
highli
pathogen
zoonot
agent
orthonairoviru
genu
within
nairovirida
princip
reservoir
cchfv
ixodid
hard
tick
primarili
belong
genu
hyalomma
tick
maintain
viru
natur
feed
small
mammal
ungul
bird
within
thirti
countri
across
eastern
hemispher
human
infect
occur
bite
infect
tick
exposur
infect
anim
product
nosocomi
transmiss
cchfv
casefat
rate
outbreak
rang
though
higher
rate
document
instanc
cchfv
categor
categori
prioriti
pathogen
us
nation
institut
health
due
associ
morbid
mortal
potenti
public
healthsociet
impact
well
lack
approv
therapeut
option
useu
licens
vaccin
treatment
guanosin
analogu
ribavirin
suggest
therapeut
given
earli
human
infect
howev
efficaci
clearli
demonstr
clinic
trial
cchf
reason
vaccin
therapeut
countermeasur
cchfv
current
develop
full
partial
matur
cchfv
particl
contain
singl
strand
tripartit
neg
sens
rna
genom
small
medium
larg
l
segment
respect
encod
structur
nucleoprotein
np
two
envelop
protein
g
n
g
c
viral
rnadependentrnapolymeras
rdrp
msegment
contain
kilobas
openread
frame
code
glycoprotein
precursor
polypeptid
gpc
host
cell
process
cleavag
event
posttransl
modif
gpc
yield
two
matur
structur
glycoprotein
g
n
g
c
along
sever
nonstructur
glycoprotein
aid
structur
g
n
g
c
matur
two
glycoprotein
like
respons
pertin
event
viral
replic
cycl
viral
attach
cell
entri
tissu
tropism
induct
protect
immun
respons
seen
similarli
member
bunyaviral
latter
demonstr
cchfv
use
monoclon
antibodi
mab
direct
g
n
g
c
demonstr
vitro
neutral
tissu
cultur
vivo
passiv
protect
suckl
mice
data
suggest
gpc
would
import
antivir
target
therapeut
vaccin
effort
initi
attempt
use
dna
clone
recoveri
system
design
lawson
et
al
fail
produc
infecti
cchfvgpc
fig
overcom
use
modif
base
system
describ
whitt
reli
tran
vsv
glycoprotein
g
complement
vsvg
virion
techniqu
allow
vsvg
incorpor
recoveri
facilit
effici
assembl
genom
without
need
cchfvgpc
particip
initi
infect
recov
virion
fig
recov
virion
contain
cchfvgpc
genom
vsvg
complement
design
vsvg
contribut
singlecycl
infect
unless
vsvg
provid
tran
viru
replic
effect
cell
cultur
initi
recoveri
vsvg
viru
passag
vsvg
complement
bhk
cell
passag
onto
uncompl
normal
bhk
cell
unabl
isol
infecti
viru
initi
supernat
howev
seven
total
serial
passag
supernat
uncompl
bhk
cell
result
eventu
cytopath
effect
cpe
cell
cultur
fociplaqu
format
appear
monolay
monolay
cpe
harvest
rna
stain
cchfvgpc
antigen
via
immunofluoresc
assay
found
posit
data
shown
replic
compet
construct
design
fig
sanger
sequenc
construct
use
primer
vsv
backbon
cchfvgpc
orf
carri
confirm
genom
reveal
sever
singl
nucleotid
polymorph
snp
data
shown
next
gener
sequenc
ng
perform
confirm
sanger
result
detail
snp
within
entir
genom
construct
supplement
tabl
ng
sequenc
demonstr
fourteen
ident
singl
nucleotid
polymorph
snp
preserv
replic
defici
replic
compet
construct
replic
compet
construct
possess
four
addit
nonsynonym
mutat
within
cchfvgpc
fig
supplement
tabl
henceforth
refer
two
mutat
within
cchfvgpc
replic
compet
construct
result
truncat
fourteen
amino
acid
ctermin
tail
g
c
fig
assess
growth
kinet
compar
authent
cchfv
perform
singlecycl
growth
curv
analysi
bhk
cell
infect
respect
virus
variou
time
interv
hr
post
infect
hpi
full
monolay
destruct
rvsvgfp
wildtyp
control
peak
titer
approxim
hpi
cchfv
prototypestrain
peak
hpi
fig
replic
compet
pseudotyp
peak
titer
approxim
hpi
fig
assess
express
cchfvgpc
vector
perform
immunofluoresc
assay
use
mab
bind
either
cchfvg
c
g
n
assay
reveal
strong
vitro
express
antigen
fig
addit
examin
cchfvg
c
incorpor
onto
rvsv
virion
use
coomassi
stain
western
blot
analysi
gradient
purifi
semipurifi
rvsvgfp
cchfv
control
coomassi
stain
differ
number
mobil
protein
band
detect
among
wt
rvsvgfp
fig
lane
cchfvgpc
recombin
addit
protein
band
kda
analog
band
detect
cchfv
virion
pellet
fig
lane
cchfvgpc
recombin
also
possess
pronounc
protein
band
kda
compar
wt
rvsvgfp
fig
lane
cchfv
structur
glycoprotein
g
n
g
c
present
band
approxim
kda
kda
respect
fig
lane
sdspage
gel
observ
g
n
band
found
cchfvgpc
recombin
kda
howev
two
distinct
band
kda
recombin
fig
lane
encod
vsvg
confirm
deep
sequenc
shown
supplement
tabl
complement
vsvg
seven
round
bhk
passag
duplic
protein
gel
run
probe
western
blot
use
mab
previous
identifi
specif
cchfvg
c
western
blot
mab
bei
resourc
current
avail
antibodi
probe
sole
matur
g
n
western
blot
western
blot
data
demonstr
limit
nonspecif
bind
three
vsv
protein
observ
lane
rvsvgfp
fig
lane
show
strong
signal
least
two
antigen
approxim
kda
kda
fig
lane
indic
matur
cchfvg
c
potenti
precursor
molecul
oligomer
form
cchfvg
c
due
lack
antigen
prepar
incorpor
inon
virion
semipurifi
cchfv
also
show
limit
nonspecif
bind
antigen
kda
cchfvnp
kda
cchfvg
n
distinct
signal
kda
cchfvg
c
fig
lane
examin
ultrastructur
transmiss
electron
microscopi
studi
conduct
particl
rvsvgfp
wildtyp
vsv
electron
microscopi
control
observ
nm
fig
top
consist
rvsv
pseudotyp
bunyaviru
gp
pseudotyp
maintain
rhabdoviru
morpholog
classic
bullet
shape
coil
intravirion
structur
fig
bottom
particl
observ
length
rang
nm
fig
bottom
appar
length
increas
like
due
genom
contain
approxim
extra
nucleotid
comparison
rvsvgfp
genom
also
slightli
larger
nativ
wildtyp
vsv
indiana
genbank
number
addit
immunolabel
employ
mab
cchfvg
c
counterstain
nm
gold
conjug
secondari
mab
fig
bottom
immunolabel
demonstr
label
g
c
spike
virion
surfac
fig
bottom
data
support
replic
compet
construct
express
cchfvgp
vitro
addit
express
cchfvg
c
surfac
virion
vivo
studi
design
test
abil
construct
function
experiment
vaccin
mous
model
cchfv
select
test
construct
protect
efficaci
pilot
studi
supplement
fig
replic
defici
construct
vsvg
fail
provid
protect
howev
replic
compet
construct
demonstr
protect
depend
dose
base
result
initi
pilot
studi
elect
adjust
vaccin
challeng
dose
administ
pfudos
replic
compet
viru
prime
boost
group
five
mice
respect
fig
control
use
pb
mock
vaccin
singl
mous
succumb
boost
group
leav
four
mice
challeng
boost
group
day
boost
day
post
prime
mice
challeng
pfu
cchfv
strain
monitor
clinic
sign
weight
temperatur
challeng
humanclin
strain
design
throughout
work
previous
publish
genbank
access
number
ssegment
msegment
lsegment
mean
timetodeath
mtd
day
post
infect
dpi
standard
deviat
sd
dpi
demonstr
pb
control
group
fig
prime
boost
group
protect
observ
dpi
fig
prime
wwwnaturecomscientificreport
wwwnaturecomscientificreport
pb
group
display
weight
loss
boost
group
show
weight
loss
fig
three
group
display
elev
temperatur
first
three
day
post
challeng
fig
result
indic
prime
group
show
mark
ill
boost
group
display
observ
diseas
examin
humor
respons
vaccin
mice
sera
group
analyz
igg
cchfvgp
presenc
cchfv
neutral
antibodi
separ
group
anim
vaccin
n
per
group
similar
primeboost
dose
bled
day
assess
prechalleng
immun
statu
circul
igg
cchfvgp
detect
sera
vaccin
group
begin
day
found
increas
substanti
end
studi
fig
curious
studi
end
point
prime
group
display
higher
titer
compar
prime
plu
boost
group
fig
indic
prime
group
higher
concentr
igg
studi
endpoint
recogn
cchfvgp
compar
boost
group
reciproc
titer
pb
group
neglig
igg
respons
cchfvgp
fig
determin
neutral
activ
sera
plaqu
reduct
neutral
test
prnt
carri
use
challeng
isol
depict
fig
prime
group
neutral
antibodi
titer
prnt
boost
group
prnt
studi
endpoint
fig
prnt
posit
control
hyperimmun
mous
ascit
fluid
hmaf
kindli
provid
ksiazek
galveston
texa
rais
cchfv
expos
mice
show
prnt
pb
control
mice
demonstr
prnt
valu
fig
particl
prepar
stain
c
mab
use
hrpconjug
secondari
e
transmiss
electron
micrograph
rvsvgfp
replic
compet
particl
bhk
cell
semipurifi
use
sucros
cushion
purifi
use
iodixanol
gradient
centrifug
neg
stain
aqueou
uranyl
acet
immunolabel
c
mab
secondari
nm
gold
label
secondari
sampl
fix
glutaraldehyd
imag
adjust
bright
contrast
format
size
display
purpos
coomassi
gel
western
blot
imag
crop
imag
file
imag
paramet
eas
view
gel
blot
origin
avail
supplement
inform
origin
raw
data
file
avail
upon
request
wwwnaturecomscientificreport
wwwnaturecomscientificreport
addit
studi
endpoint
cohort
examin
tissu
immunohistochemistri
ihc
cchfvnp
antigen
control
cohort
mark
cchfvnp
immunolabel
hepatocyt
within
liver
section
fig
liver
section
prime
boost
cohort
observ
wwwnaturecomscientificreport
wwwnaturecomscientificreport
cchfvnp
immunolabel
fig
b
examin
spleen
tissu
section
observ
control
cohort
mark
cchfv
immunolabel
mononuclear
cell
fig
prime
cohort
cytoplasm
mild
diffus
immunolabel
mononuclear
cell
primarili
red
pulp
fig
boost
cohort
specif
cchfv
immunolabel
within
spleen
section
fig
studi
vari
success
express
cchfvgpc
tran
viral
vector
rvsv
cchfvgpc
like
challeng
due
numer
posttransl
modif
requir
matur
yield
function
cchfvgpc
addit
cchfvgpc
form
immatur
cchfv
particl
golgi
egress
via
vesicular
transport
unlik
cchfv
vsv
bud
plasma
membran
hamper
effort
recov
replic
vector
cchfvgpc
express
use
mammalian
wwwnaturecomscientificreport
wwwnaturecomscientificreport
codon
optim
cchfvgpc
demonstr
express
cchfvg
c
cell
surfac
maintain
nativ
cchfvgpc
matur
factor
hypothes
express
due
codon
optim
could
facilit
shuttl
cchfvgp
plasma
membran
vsv
could
acquir
bud
function
compon
gpc
viral
envelop
although
abl
drive
strong
express
cchfvgpc
vitro
unabl
gener
replic
compet
pseudotyp
viru
without
initi
use
vsvg
tran
multipl
studi
examin
pseudotyp
rvsv
cchfvgpc
use
plasmid
encod
backbon
luciferas
report
pseudotyp
tran
express
cchfvgpc
develop
cell
shtanko
et
al
suda
et
al
also
perform
similar
pseudotyp
tran
express
cell
variou
full
length
gpc
modifi
gpc
construct
contain
truncat
g
c
cterminalendodomain
tail
pseudotyp
also
luciferas
gfp
orf
genom
encod
backbon
publish
pseudotyp
cchfvgpc
system
use
neutral
entryinfect
studi
howev
construct
character
western
blot
immun
electron
microscopi
understand
pseudotyp
envelop
either
construct
selfrepl
capabl
express
antigen
element
cchfvgpc
post
infect
tool
current
avail
abl
detect
western
blot
electron
microscopi
form
cchfvg
c
present
function
surfac
virion
current
situat
reagent
matur
cchfvg
n
limit
assay
particular
antigen
commerci
avail
antibodi
target
precursor
molecul
cchfvpreg
n
immun
electron
microscopi
demonstr
cchfvg
c
incorpor
surfac
virion
abl
immunolabel
cchfvg
c
page
coomassi
stain
analysi
purifi
virion
lysat
reveal
promin
protein
band
kda
posit
estim
size
matur
g
n
nonetheless
three
smaller
protein
band
prepar
similar
protein
profil
shown
vector
cchfvgpc
prepar
shown
buttigieg
et
al
possibl
protein
band
may
also
correspond
altern
initi
downstream
start
codon
present
orf
vsvm
focu
current
studi
observ
warrant
character
vector
use
tool
studi
cchfvgpc
mechan
suda
et
al
shown
increas
amount
infecti
pseudotyp
cchfvg
c
tail
truncat
delet
residu
end
ctermin
cchfvg
c
tail
data
support
region
probabl
least
contributori
mechan
enabl
replic
compet
pseudotyp
format
pseudotyp
also
found
contain
ctermin
cchfvg
c
tail
truncat
fig
like
local
retent
signal
within
transmembran
region
endodomain
tail
aberr
fail
transport
cchfvg
c
sole
intracellular
compart
may
turn
permit
shuttl
plasma
membran
focu
studi
although
examin
futur
interest
note
similar
motif
demonstr
bunyavirus
also
demonstr
vsv
pseudotyp
structur
cchfvg
c
shown
import
protein
cchfv
contain
put
receptor
bind
region
mammalian
cell
surfac
nucleolin
class
ii
viral
fusion
domain
neutral
epitop
human
linear
bcell
epitop
site
replic
compet
rvsv
vector
enabl
explor
compon
lower
contain
without
need
transfect
tran
express
cchfvgpc
onto
system
explor
use
rvsv
express
cchfvgp
potenti
vaccin
immunocompromis
mice
concern
murin
virul
observ
wildtyp
vsv
studi
rvsv
express
hemorrhag
fever
viru
gp
demonstr
lethal
outcom
model
hamper
anim
platform
serv
vaccin
develop
tool
vaccin
mice
succumb
prime
dose
inform
conduct
sever
pilot
studi
examin
effect
dose
challeng
strategi
replic
defici
vsvg
replic
compet
construct
demonstr
safeti
profil
construct
supplement
fig
neither
group
attribut
fatal
due
vaccin
howev
replic
compet
construct
demonstr
protect
select
cchfv
challeng
isol
chose
isol
low
passag
histori
demonstr
clinic
relev
ie
document
histori
diseas
human
isol
came
clinic
case
elisa
prnt
experi
studi
endpoint
sera
demonstr
humor
igg
respons
cchfvgpc
observ
neutral
antibodi
produc
prime
group
receiv
high
pfu
dose
fig
b
curious
boost
pfu
group
lower
detect
antibodi
cchfvgpc
lower
neutral
titer
fig
b
clinic
data
group
follow
cchfv
challeng
show
prime
group
elev
temperatur
weight
loss
addit
two
anim
cohort
display
clinic
sign
includ
rough
fur
indic
ill
cchfv
challeng
fig
c
data
shown
boost
group
display
elev
temperatur
neither
substanti
weight
loss
detect
observ
chang
clinic
score
anim
fig
c
data
shown
analysi
tissu
studi
end
point
cohort
also
reveal
immunolabel
liver
vaccin
anim
prime
cohort
diffus
cytoplasm
immunolabel
mononuclear
cell
spleen
section
fig
find
along
clinic
score
suggest
replic
cchfv
prime
group
compar
boost
group
could
potenti
lead
higher
anticchfvgpc
igg
titer
prime
cohort
studi
endpoint
cchfv
challeng
may
serv
heterolog
booster
increas
level
compar
boost
cohort
fig
b
regardless
protect
achiev
regimen
although
boost
group
data
suggest
studi
endpoint
observ
igg
titer
cchfvgpc
along
lower
neutral
titer
prnt
evid
abil
combat
lethal
cchfv
infect
mous
model
vaccin
fig
b
wwwnaturecomscientificreport
wwwnaturecomscientificreport
correl
protect
cchf
difficult
defin
due
multipl
vaccin
deliveri
platform
examin
date
sever
cchfv
experiment
vaccin
studi
identifi
cellmedi
humor
involv
instanc
neutral
antibodi
product
look
known
human
cchf
survivor
mount
humor
respons
wherea
succumb
typic
lack
igg
respons
studi
examin
antibodi
neutral
respons
variou
vaccin
platform
dna
vaccin
follow
three
round
vaccin
regimen
induc
detect
antibodi
neutral
capac
observ
prnt
dilut
achiev
protect
depend
antigen
encod
dna
plasmid
cell
cultur
base
inactiv
viru
vaccin
achiev
high
igg
titer
high
neutral
respons
howev
also
requir
three
vaccin
round
alum
adjuv
confer
protect
clinic
isol
ifnar
mice
antibodi
titer
neutral
capac
challeng
viru
present
similar
though
vsv
platform
achiev
greater
protect
singl
dose
studi
along
suggest
facet
immun
system
like
involv
confer
complet
protect
studi
proof
concept
studi
correl
studi
cell
respons
evalu
could
contributori
group
shown
establish
new
vector
provid
protect
benefit
futur
studi
tempor
examin
antibodi
cell
repertoir
prime
boost
dose
follow
cchfv
challeng
would
inform
mous
model
futur
use
murin
model
might
provid
addit
insight
use
intact
murin
immun
system
vaccin
lethal
model
cchfv
infect
ideal
immunocompet
larger
anim
model
greatli
need
cchf
field
test
array
cchfv
experiment
vaccin
shown
promis
mous
model
promis
step
forward
appear
nonhuman
primat
diseas
model
recent
develop
howev
cchf
model
appear
strain
challeng
rout
depend
conclus
studi
offer
tool
studi
biolog
cchfv
relat
structur
g
c
also
serv
develop
character
replic
compet
pseudotyp
relat
cchf
vaccin
develop
replic
compet
construct
provid
protect
observ
humor
respons
singleinject
human
isol
challeng
strain
inform
valuabl
design
futur
studi
cchfv
anim
model
establish
character
tool
examin
biolog
structur
cchfvg
c
pseudotyp
rvsv
system
ksiazek
utmb
world
refer
center
emerg
virus
arbovirus
galveston
tx
propag
vero
cell
plu
previou
passag
suckl
mice
vero
cell
sinc
isol
vitro
vivo
work
cchfv
perform
biosafeti
level
facil
galveston
nation
laboratori
univers
texa
medic
branch
galveston
tx
cell
viral
stock
test
free
mycoplasma
pcr
kit
intronbio
gyunggdo
south
korea
monoclon
antibodi
mab
c
n
antibodi
gener
character
describ
previous
describ
antibodi
avail
bei
resourc
atcc
except
kindli
provid
unit
state
arm
forc
research
institut
infecti
diseas
frederick
md
gener
vector
rvsv
vector
clone
recov
cdna
previous
describ
briefli
bluescript
backbon
plasmid
polymeras
promot
control
encod
vsv
indiana
backbon
express
chimer
zair
ebolaviru
chebov
glycoprotein
gp
use
vector
design
plasmid
modifi
cut
exist
chebovgp
code
sequenc
via
mlui
nhei
restrict
site
yield
vector
insert
code
codon
optim
open
read
frame
complet
cchfv
glycoprotein
precursor
gpc
digest
ligat
vector
cchfvgpc
insert
creat
overhang
pcr
mutagenesi
flank
mlui
restrict
site
plu
kozak
sequenc
xbai
restrict
site
pcr
amplifi
codon
optim
pcaggcchfvgpc
kindli
provid
j
kortekaa
central
veterinari
institut
lelystad
netherland
ligat
clone
plasmid
design
transfect
bhk
cell
also
cotransfect
vsv
protein
n
p
g
l
helper
plasmid
promot
control
driven
infect
moi
recombin
vaccinia
viru
express
polymeras
kindli
provid
whitt
recov
viru
design
vsvg
collect
hr
post
infect
transfect
filter
twice
filter
remov
vaccinia
viru
plaqu
purifi
onto
vsvg
complement
bhk
cell
store
use
plasmid
map
clone
primer
sequenc
avail
upon
request
infect
enumer
growth
kinet
prepar
viral
materi
infect
replic
defici
vector
semiconflu
monolay
bhk
cell
transfect
lipofectamin
wwwnaturecomscientificreport
wwwnaturecomscientificreport
ltx
invitrogen
cell
use
pcaggvsvg
indiana
monolay
display
cell
round
syncytia
infect
moi
vsvg
supernat
harvest
hr
post
infect
hpi
clarifi
rpm
min
confluent
monolay
bhk
cell
infect
replic
compet
moi
hr
co
rock
min
interv
harvestedclarifi
hpi
plaqu
assay
viral
titrat
carri
analog
manner
overlay
media
final
concentr
avicel
fmc
biopolym
philadelphia
pa
eagl
minimum
essenti
medium
mem
fb
ps
bhk
cell
hpi
incub
overlay
aspir
buffer
formalin
fix
crystal
violet
stain
incub
onto
monolay
one
hr
plaqu
enumer
plaqu
form
unit
pfu
determin
averag
technic
replic
per
sampl
singlecycl
growth
curv
moi
perform
absorb
rvsvgfp
cchfv
onto
duplic
monolay
bhk
cell
sixwel
plate
describ
inoculum
aspir
cell
wash
three
time
pb
ad
monolay
incub
variou
time
point
indic
fig
design
time
point
sampl
collect
clarifi
store
titrat
perform
describ
cchfvg
c
protein
analysi
immunofluoresc
analysi
carri
infect
monolay
moi
hpi
cell
fix
wv
paraformaldehyd
permeabil
triton
stain
dilut
mab
cell
wash
block
bsa
incub
dilut
secondari
mab
conjug
fluorescein
isothiocyan
fitc
invitrogen
cell
mount
counterstain
nuclear
stain
dapi
invitrogen
stain
cell
examin
nikon
eclips
ti
fluoresc
microscop
whole
virion
analyz
infect
bhk
cell
monolay
semipurifi
clarifi
supernat
sucros
cushion
rpm
min
use
beckman
sw
ti
rotor
viral
pellet
lyse
use
proteas
inhibitor
cocktail
invitrogen
recombin
vsv
lysat
incub
min
protein
subsequ
quantifi
use
bca
protein
assay
per
manufactur
instruct
thermo
fisher
scientif
waltham
per
institut
inactiv
protocol
cchfv
lysat
modifi
inactiv
protocol
use
instead
laemmli
sampl
buffer
lsb
thermo
fisher
scientif
min
boil
transfer
fresh
tube
approxim
ng
purifi
semipurifi
virion
associ
total
protein
mix
lsb
without
run
gradient
miniprotean
tgx
electrophoresi
gel
biorad
hercul
california
coomasi
stain
accomplish
via
incub
tgx
gel
coomassi
fluor
orang
protein
gel
stain
thermo
fisher
scientif
per
manufactur
instruct
imag
nm
gel
doc
xr
gel
document
system
biorad
western
blot
run
tgx
gel
use
wet
tank
transfer
hybondp
polyvinyliden
difluorid
pvdf
membran
ge
healthcar
littl
chalfont
uk
membran
block
bsa
overnight
tween
sigmaaldrich
follow
incub
primari
mab
dilut
overnight
secondari
hors
radish
peroxidas
hrp
conjug
antibodi
thermo
fisher
scientif
dilut
incub
membran
h
room
temperatur
detect
hrp
accomplish
via
pierc
ecl
western
blot
substrat
thermo
fisher
scientif
hyperfilm
ecl
ge
healthcar
kodak
carestream
film
xomat
processor
eastman
kodak
compani
rochest
ny
place
trizol
ls
thermo
fisher
scientif
ratio
mix
incub
min
room
temperatur
transfer
fresh
tube
rna
isol
sampl
mixtur
use
zymo
research
directzol
rna
minprep
zymo
research
corp
irvin
ca
per
manufactur
instruct
rna
quantifi
use
nanodrop
thermo
fisher
scientif
approxim
ng
total
rna
use
creat
cdna
use
superscript
iii
firststrand
synthesi
system
invitrogen
vsvm
matrix
protein
gene
forward
primer
sanger
sequenc
cdna
perform
use
vsvm
vsvl
cchfvgpc
codon
optim
open
read
frame
primer
set
accomplish
utmb
molecular
genom
core
use
abi
prism
dna
sequenc
appli
biosystem
foster
citi
ca
sequenc
analysi
perform
use
geneiou
biomatt
auckland
new
zealand
base
consensu
plasmid
map
cdnasequenc
primer
consensusplasmid
map
avail
upon
request
analyz
stock
cchfv
rvsv
vaccin
vector
use
studi
perform
deep
sequenc
analysi
rna
isol
viru
stock
briefli
viral
rna
isol
trizol
ls
invitrogen
sampl
mixtur
use
directzol
rna
miniprep
zymo
research
per
manufactur
instruct
approxim
ng
purifi
rna
use
make
cdna
use
ovat
rnaseq
kit
nugen
turn
use
prepar
doublestrand
dna
librari
use
encor
ion
torrent
librari
prep
kit
sequenc
perform
utmb
molecular
core
ion
torrent
use
deep
sequenc
chip
sequenc
analysi
perform
use
dna
star
seqman
ngen
softwar
dna
star
base
unpair
analysi
base
pair
overlap
ultrastructur
analysi
virus
propag
multipl
flask
confluent
bhk
cell
viral
supernat
harvest
clarifi
describ
clarifi
supernat
concentr
mix
buffer
polyethylen
glycol
incub
hr
follow
centrifug
min
concentr
pellet
resuspend
pb
proteas
inhibitor
overlaid
atop
optiprep
sigmaaldrich
continu
gradient
buffer
iodixanol
virus
band
ultracentrifug
wwwnaturecomscientificreport
wwwnaturecomscientificreport
em
hatfield
pa
min
incub
mab
dilut
antibodi
absorb
min
wet
chamber
wash
pb
contain
bsa
incub
secondari
antibodi
conjug
nm
colloid
gold
particl
em
dilut
min
grid
wash
pb
bsa
fix
use
wv
aqueou
glutaraldehyd
min
final
stain
wv
aqueou
uranyl
acet
grid
examin
kv
use
philip
transmiss
electron
microscop
ethic
care
vaccin
anim
challeng
anim
studi
approv
utmb
institut
anim
care
use
committe
iacuc
anim
research
carri
complianc
anim
welfar
act
feder
regul
stipul
regard
anim
adher
guid
care
use
laboratori
anim
nation
research
council
anim
facil
research
conduct
accredit
associ
assess
accredit
laboratori
anim
care
intern
studi
use
femal
week
old
mice
tacon
germantown
ny
acclimat
period
barrier
condit
environment
enrich
steril
hous
mice
anesthet
isofluran
implant
subderm
transpond
provid
code
identifi
permit
bodi
temperatur
measur
biomed
data
solut
seaford
de
vaccin
prepar
dilut
hank
balanc
salt
medium
fb
along
pb
control
group
anesthesia
isofluran
ul
prepar
administ
intraperiton
ip
five
mice
per
experiment
group
clinic
score
bodi
temperatur
weight
record
daili
day
post
vaccin
prime
mice
challeng
ul
ip
either
pfu
refer
howev
pfu
calcul
back
titer
challeng
prepar
administr
thu
report
fig
respect
challeng
dose
frozen
storag
verifi
backtitr
plaqu
assay
cell
outlin
challeng
anim
observ
clinic
score
temperatur
weight
chang
upon
reach
institut
approv
endpoint
score
criteria
studi
endpoint
blood
sampl
collect
contain
collect
tube
granier
usa
plasma
separ
frozen
storag
analysi
euthanasia
criteria
defin
mous
display
sever
hunch
postur
inabl
reluct
move
appear
weak
stagger
move
around
cage
labor
breath
weight
loss
greater
start
bodi
weight
anticchfvgpc
igg
elisa
develop
iodixanol
gradient
purifi
rvsvgfp
resuspend
buffer
bca
protein
quantifi
previous
describ
use
whole
virion
antigen
coat
immunosorb
plate
thermo
fisher
scientif
matric
variou
antigen
block
primari
antibodi
hyperimmun
mous
ascet
fluid
hmaf
kindli
provid
ksiazek
cchfvcchfvgpc
secondari
antibodi
mab
concentr
use
develop
optim
detect
condit
cchfvgpc
via
elisa
per
optim
one
microgram
purifi
antigen
per
ml
suspend
steril
filter
sodium
bicarbcarbon
buffer
ph
allow
incub
immunosorb
plate
overnight
plate
wash
pb
contain
concentr
thimeros
block
occur
milk
dissolv
wash
buffer
hr
room
temperatur
sera
mice
ad
dilut
pipet
across
plate
allow
incub
one
hr
plate
wash
secondari
antimous
antibodi
conjug
hrp
ad
dilut
one
hr
abt
peroxidas
substrat
kpl
seracar
life
scienc
milford
incub
min
room
temperatur
prior
addit
sd
stop
solut
plate
read
nine
read
per
well
nm
plastic
correct
factor
account
nm
read
per
well
test
sera
evalu
use
purifi
rvsvgfp
antigen
plaqu
reduct
neutral
assay
serial
dilut
sera
four
mice
per
treatment
group
aliquot
cluster
tube
allow
incub
pfu
cchfv
isol
turkey
approxim
hr
ice
result
sera
plu
viru
mixtur
overlaid
onto
plate
confluent
cell
absorb
hr
co
rock
min
interv
plaqu
assay
carri
manner
describ
previou
method
section
result
plaqu
enumer
viru
sera
well
compar
sera
plu
media
well
run
sampl
percent
neutral
calcul
report
dilut
hyperimmun
mous
ascit
fluid
hmaf
rais
cchfv
addit
serial
dilut
run
posit
control
immunohistochemistri
tissu
tissu
section
deparaffin
rehydr
xylen
grade
ethanol
slide
went
heat
antigen
retriev
steamer
min
sigma
citrat
buffer
sigma
aldrich
st
loui
mo
block
endogen
peroxidas
activ
slide
treat
hydrogen
peroxid
rins
distil
water
tissu
section
process
ihc
use
thermo
autostain
thermofish
kalamazoo
mi
sequenti
min
incub
avidin
biotin
solut
vector
burlingam
ca
perform
block
endogen
biotin
reactiv
specif
anticchfv
immunoreact
detect
use
primari
polyclon
antibodi
ibt
bioservic
rockvil
md
dilut
min
secondari
biotinyl
vector
laboratori
burlingam
ca
dilut
min
follow
vector
horseradish
peroxidas
streptavidin
rtu
vector
min
slide
develop
dako
dab
chromagen
dako
carpenteria
ca
min
counterstain
harri
hematoxylin
second
tissu
section
uninfect
mice
use
neg
control
